Curaleaf Holdings Inc.

Curaleaf has announced a 1-for-3 reverse stock split to be effective on or about June 5, 2026, intended to meet U.S. exchange minimum price requirements and enable a potential uplisting. The move will reduce outstanding common shares from 698,728,008 to approximately 232,909,336 and will proportionally adjust options and convertible instruments. The stock will continue trading under the ticker CURA on the Toronto Stock Exchange; the company reports a market capitalization of about $2.7 billion and trailing twelve‑month revenue of $1.29 billion. Analyst price targets cited in the report range from $3.86 to $4.77. » More on de.investing.com

Curaleaf has appointed Torsten Greif, co-founder of Four 20 Pharma, to its board of directors. Four 20 Pharma, in which Curaleaf holds a majority stake, is a German cannabis producer with EU-GMP and GDP licences. Curaleaf intends to use Greif’s local expertise to advance the expansion of its European activities and the supply of EU-GMP‑certified medical cannabis to Germany and other markets. » More on de.investing.com

Curaleaf has opened a new dispensary in Findlay, Ohio, increasing its presence in the state to five locations. The site offers cannabis products to medical patients and recreational customers, including the brands Select BRIQ, Find and Grassroots. In total, Curaleaf now operates 162 retail stores in the U.S. » More on de.investing.com